SGLT1

SGLT1 Inhibitors (29)

SGLT1 Related Products (31):

By Type:	Pan (10) Selective (7)

Cat. No.	Product Name	Effect	Purity

HY-N0142

Phloretin	Inhibitor	99.92%
Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Malus pumila Mill.，has anti-inflammatory activities. Phloridzin is a specific，competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). Phloretin inhibits Yeast-made GLUT1 as well as Human erythrocyte GLUT1 with IC₅₀values of 49 μM and 61 μM，respectively.Phloretin has the potential for the treatment of rheumatoid arthritis (RA) and allergic airway inflammation.

HY-15516

Sotagliflozin	Inhibitor	99.94%
Sotagliflozin (LX-4211) is a potent dual SGLT2/1 inhibitor. Antidiabetic agents.

HY-N0143

Phlorizin	Inhibitor	99.93%
Phlorizin (Floridzin) is an orally active non-selective sodium-glucose cotransporter (SGLT) inhibitor, with an IC₅₀ of 0.04 μM and a K_i of 39 nM against hSGLT2, and an IC₅₀ of 0.17 μM and a K_i of 0.31 μM against hSGLT1. Phlorizin promotes GLUT4 translocation, inhibits gluconeogenesis and promotes glycogen synthesis by activating the PI3K/Akt/mTOR pathway. Phlorizin reduces DNA damage and apoptosis (apoptosis) by inhibiting the NF-κB inflammatory pathway. Phlorizin induces apoptosis via activating the Caspase pathway by antagonizing the JAK/STAT3 and PCK pathways. Phlorizin also exhibits antibacterial, anti-inflammatory and neuroprotective activities.

HY-14894

Ipragliflozin	Inhibitor	99.71%
Ipragliflozin (ASP1941) is an orally active and selective SGLT2 inhibitor with IC₅₀s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent.

HY-17638

Mizagliflozin	Inhibitor	99.20%
Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective SGLT1 inhibitor, with a K_i of 27 nM for human SGLT1. Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic agent that can modify postprandial blood glucose excursion. Mizagliflozin also exhibits potential in the amelioration of chronic constipation.

HY-17604

Bexagliflozin	Inhibitor	99.31%
Bexagliflozin (EGT1442) is an orally active and selective SGLT2 inhibitor with IC₅₀ values of 0.002 μM and 5.6 μM for SGLT2 and SGLT1, respectively. Bexagliflozin selectively inhibits SGLT2-mediated sodium-dependent glucose uptake. Bexagliflozin induces saturable urinary glucose excretion in normal rats and dogs. Bexagliflozin reduces blood glucose and HbA_1c levels in db/db mice without affecting body mass or insulin level. Bexagliflozin can be used for the research of type 2 diabetes mellitus, hypertensive stroke.

HY-180784

Hypoglycemic agent 4
Hypoglycemic agent 4 (Compound 5b) is a tetrahydroacridine derivative with orally active hypoglycemic activity. Hypoglycemic agent 4 has a good binding affinity for the key diabetic targets: DPP-IV, SGLT1, and GLUT2. Hypoglycemic agent 4 can inhibit glucose diffusion. Hypoglycemic agent 4 can reduce fasting blood sugar in Streptozotocin (HY-13753)-induced diabetic rats and its effect is comparable to Gliclazide (HY-B0753). Hypoglycemic agent 4 can be used for research of type 2 diabetes.

HY-186207

Demethyl-LX2761	Inhibitor
Demethyl-LX2761 is a selective sodium-glucose cotransporter 1 (SGLT1) inhibitor. Demethyl-LX2761 can be used for the research of type 2 diabetes.

HY-N4100

Trilobatin	Inhibitor	98.90%
Trilobatin, a natural sweetener derived from Lithocarpus polystachyus Rehd, Trilobatin is an HIV-1 entry inhibitor targeting the HIV-1 Gp41 envelope. Neuroprotective effects. Trilobatin is also a SGLT1/2 inhibitor that selectively induces the proliferation of human hepatoblastoma cells.

HY-10449

Luseogliflozin	Inhibitor	99.33%
Luseogliflozin (TS 071) is a potent, selective, orally active sodium-dependent glucose cotransporter (SGLT) 2 inhibitor, with an IC₅₀ of 2.26 nM, about 1765-fold selectivity over SGLT1 (IC₅₀, 3990 nM). Luseogliflozin has the protential for researching type 2 diabetes.

HY-14945

Remogliflozin etabonate	Inhibitor	99.64%
Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with K_i values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models.

HY-N0143A

Phlorizin dihydrate	Inhibitor	99.51%
Phlorizin (Floridzin) dihydrate is an orally active non-selective sodium-glucose cotransporter (SGLT) inhibitor, with an IC₅₀ of 0.04 μM and a K_i of 39 nM against hSGLT2, and an IC₅₀ of 0.17 μM and a K_i of 0.31 μM against hSGLT1. Phlorizin dihydrate promotes GLUT4 translocation, inhibits gluconeogenesis and promotes glycogen synthesis by activating the PI3K/Akt/mTOR pathway. Phlorizin dihydrate reduces DNA damage and apoptosis (apoptosis) by inhibiting the NF-κB inflammatory pathway. Phlorizin dihydrate induces apoptosis via activating the Caspase pathway by antagonizing the JAK/STAT3 and PCK pathways. Phlorizin dihydrate also exhibits antibacterial, anti-inflammatory and neuroprotective activities.

HY-109092

Licogliflozin	Inhibitor	98.03%
Licogliflozin is a sodium glucose cotransporter (SGLT1 and SGLT2) inhibitor.

HY-N0142R

Phloretin (Standard)	Inhibitor
Phloretin (Standard) is the analytical standard of Phloretin. This product is intended for research and analytical applications. Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Malus pumila Mill., has anti-inflammatory activities. Phloridzin is a specific, competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). Phloretin inhibits Yeast-made GLUT1 as well as Human erythrocyte GLUT1 with IC₅₀values of 49 μM and 61 μM, respectively.Phloretin has the potential for the treatment of rheumatoid arthritis (RA) and allergic airway inflammation.

HY-106158

T-1095	Inhibitor	99.40%
T-1095 is a selective and orally active Na⁺-glucose cotransporter (SGLT) inhibitor with IC₅₀s of 22.8 µM and 2.3 µM for human SGLT1 and SGLT2, respectively. T-1095 can be used for diabetes research.

HY-138944

SGLT1/2-IN-1	Inhibitor
SGLT1/2-IN-1 is a dual SGLT1/SGLT2 inhibitor extract from WO2015032272A1, compound 2 .

HY-109092A

rel-Licogliflozin	Inhibitor
rel-Licogliflozin is a relative configuration of Licogliflozin (HY-109092). Licogliflozin is a sodium glucose cotransporter (SGLT1 and SGLT2) inhibitor.

HY-14810

Atigliflozin
Atigliflozin (AVE-2268) is an orally active and selective SGLT-2 inhibitor, with IC₅₀s of 10 nM and 8.2 μM for hSGLT-2 and hSGLT-1) respectively. Atigliflozin can lower the blood glucose and improve the impaired oral glucose tolerance. Atigliflozin can be used for research of type II diabetes mellitus.

HY-169821

SGLT1/2-IN-8	Inhibitor
SGLT1/2-IN-8 (compound 8) is a potent and orally active SGLT1/2 dual inhibitor with IC₅₀ values of 4 nM and 1 nM, respectively. SGLT1/2-IN-8 exhibits anti-hyperglycemic effects and can be utilized in relevant research.

HY-101122

LX2761	Inhibitor
LX2761 is an orally active, dual SGLT1/SGLT2 inhibitor with IC₅₀ values of 2.2 nM and 2.7 nM against human SGLT1 and SGLT2, respectively. LX2761 locks human SGLT1 in an outward-open conformation and blocks its putative water permeation pathway. After oral administration, LX2761 is confined exclusively to the intestinal lumen, delays intestinal glucose absorption, regulates intestinal glucose metabolism, increases cecal glucose levels, reduces cecal pH, improves glycemic control and elevates plasma total GLP-1 levels. However, LX2761 induces diarrhea in a dose-dependent manner. LX2761 can be used in diabetes-related research.

Name
Email *

	Sorry, but the email address you supplied was invalid.